Department of Urology, University Hospital Complex, Albacete, Spain,
Department of Urology, University Hospital Complex, Albacete, Spain.
Urol Int. 2020;104(3-4):293-300. doi: 10.1159/000505162. Epub 2020 Jan 21.
Recurrent urinary tract infections (R-UTIs) are very common amongst women, and alternatives to antibacterial prophylaxis are necessary. This study evaluates the effectiveness of a sublingual bacterial vaccine for the prophylaxis of R-UTIs.
We conducted a quasi-experimental pretest-posttest study of 166 women diagnosed with R-UTIs. Both before and after the start of treatment with the vaccine, we analysed the total number of R-UTI episodes, the urine culture results, and the type and number of antibiotic packages consumed. Symptoms and urine cultures were evaluated 3, 6, 9, 12, 18, and 24 months after initiating treatment with the vaccine.
The mean time of follow-up after vaccination was 1.7 years. After vaccination, there was a 54.6% reduction in episodes of UTI, and a 56.2% reduction in positive urine cultures. At 3 months, 74.4% of the patients had no R-UTI, the rate falling to 68.1% at 6 months, 52.4% at 12 months, and 44.5% at 24 months. The cumulative probability of maintaining negative urine cultures was 76% at 3 months, 37% at 12 months, and 18% at 2 years.
The use of a sublingual bacterial vaccine for the prophylaxis of R-UTIs in women is an effective treatment that contributes to a reduction in the number of UTI episodes.
复发性尿路感染（R-UTI）在女性中非常常见，因此需要替代抗菌预防措施。本研究评估了舌下细菌疫苗预防 R-UTI 的有效性。
我们对 166 名被诊断为 R-UTI 的女性进行了一项准实验性前后测试研究。在开始使用疫苗治疗前后，我们分析了 R-UTI 发作的总次数、尿液培养结果以及抗生素包的类型和数量。在开始使用疫苗治疗后 3、6、9、12、18 和 24 个月评估症状和尿液培养。
接种疫苗后的平均随访时间为 1.7 年。接种疫苗后，UTI 发作次数减少了 54.6%，尿液培养阳性率减少了 56.2%。接种后 3 个月，74.4%的患者无 R-UTI，6 个月时降至 68.1%，12 个月时降至 52.4%，24 个月时降至 44.5%。保持尿液培养阴性的累积概率在接种后 3 个月时为 76%，12 个月时为 37%，2 年时为 18%。
舌下细菌疫苗预防女性 R-UTI 是一种有效的治疗方法，可减少 UTI 发作次数。
